AOD-9604

A synthetic fragment of human growth hormone isolated to its fat-metabolism region, researched for lipolysis without HGH’s broader hormonal effects.

Typical bottle: 5 mg

Research note: AOD-9604 has been studied in humans, but clinical evidence for meaningful fat loss remains limited and should not be considered guaranteed.

What It Is

AOD-9604 is a synthetic peptide fragment derived from a specific portion of human growth hormone (HGH), developed to investigate the fat-metabolism effects associated with HGH without reproducing its full range of biological actions.

Research has primarily focused on lipolysis — breaking down stored triglycerides into fatty acids for energy — and on fat accumulation and body composition more broadly. Its appeal is a more targeted research profile than full-length HGH: it is researched specifically in the context of fat metabolism rather than as a general growth-hormone replacement.

Who May Benefit

Body-fat reduction research
Improved body-composition research
Fat metabolism and lipolysis research
Supporting a dedicated fat-loss phase alongside training

What to Expect

AOD-9604 is generally approached as a consistent, longer-term body-composition strategy rather than something expected to produce an immediate dramatic change, with results depending heavily on nutrition, activity level, and individual response.

It should not be expected to override an excessive calorie intake or replace a structured fat-loss program — it is a research tool within a broader strategy, not a standalone solution.

What to Pair It With

5-Amino-1MQ

Targets the NNMT pathway, a different metabolic mechanism that can complement AOD-9604’s fat-metabolism research.

MOTS-C

Metabolic signaling and cellular energy regulation provide a complementary mitochondrial angle.

Cagrilintide

An appetite-focused mechanism that complements AOD-9604’s fat-metabolism focus within a broader strategy.

Reconstitution

Vial

5 mg

Diluent

2 mL Acetic Acid/Glycerol or Bac. Water

Final Concentration

2.5 mg/mL

10 units = 250 mcg20 units = 500 mcg

Suggested Research Dosing Strategy

Maintenance / Lower Range

250 mcg (10 units)

Once daily, morning · subcutaneous · suggested cycle 12–16 weeks ON, 2–4 weeks OFF.

Advanced / Higher Range

500 mcg (20 units)

Once daily, morning · subcutaneous · suggested cycle 12–16 weeks ON, 2–4 weeks OFF.

Estimated 4–8 × 5 mg vials for a 12–16 week cycle, depending on the selected dose.

Administration Notes

Morning administration is common, though some split AM/PM fasted dosing per source material.

A fasted state is often incorporated, though evidence that fasting is required is limited.

Consistency throughout the research cycle matters more than expecting an immediate effect.

Research Considerations

AOD-9604’s research interest comes from isolating the fat-metabolism-associated region of the HGH molecule rather than using full-length HGH, aiming for a more targeted effect without HGH’s broader hormonal action.

Preclinical findings on lipolysis and fat metabolism are encouraging, but evidence for significant weight-loss effects specifically in humans is considerably less definitive — it is best treated as a research tool within a broader body-composition strategy.

Have a specific question about AOD-9604? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.

All Peptides by Goal